These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 19369458

  • 21. Involvement of CX3CL1/CX3CR1 axis in etanercept therapy for patients with active rheumatoid arthritis.
    Sato M, Ohtsuka K, Takahashi R, Wakabayashi K, Odai T, Isozaki T, Yajima N, Miwa Y, Kasama T.
    Open Access Rheumatol; 2011; 3():1-7. PubMed ID: 27789999
    [Abstract] [Full Text] [Related]

  • 22. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis.
    Mattey DL, Brownfield A, Dawes PT.
    J Rheumatol; 2009 Jun; 36(6):1180-7. PubMed ID: 19447930
    [Abstract] [Full Text] [Related]

  • 23. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y, Youssef SS, El Gaafary M.
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [Abstract] [Full Text] [Related]

  • 24. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 25. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
    Flendrie M, Creemers MC, Welsing PM, van Riel PL.
    Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
    [Abstract] [Full Text] [Related]

  • 26. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
    Familian A, Voskuyl AE, van Mierlo GJ, Heijst HA, Twisk JW, Dijkmans BA, Hack CE.
    Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
    [Abstract] [Full Text] [Related]

  • 27. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis.
    Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M, Ide H, Adachi M, Kasama T.
    Arthritis Rheum; 2006 Nov; 54(11):3408-16. PubMed ID: 17075825
    [Abstract] [Full Text] [Related]

  • 28. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy.
    Pavelka K, Jarosová K, Suchý D, Senolt L, Chroust K, Dusek L, Vencovský J.
    Ann Rheum Dis; 2009 Aug; 68(8):1285-9. PubMed ID: 19351624
    [Abstract] [Full Text] [Related]

  • 29. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E, Sidiropoulos P, Papadakis J, Ganotakis E, Katsikas G, Karvounaris S, Bizaki A, Kritikos H, Boumpas DT.
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [Abstract] [Full Text] [Related]

  • 30. [Clinical experience with infliximab administration in patients with rheumatoid arthritis (according to Russian register data)].
    Lukina GV, Sigidin IaA, Nasonov EL.
    Ter Arkh; 2009 Dec; 81(8):65-9. PubMed ID: 19799204
    [Abstract] [Full Text] [Related]

  • 31. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
    Haraoui B, Cameron L, Ouellet M, White B.
    J Rheumatol; 2006 Jan; 33(1):31-6. PubMed ID: 16395747
    [Abstract] [Full Text] [Related]

  • 32. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors.
    Aeberli D, Seitz M, Jüni P, Villiger PM.
    Rheumatology (Oxford); 2005 Feb; 44(2):172-5. PubMed ID: 15509629
    [Abstract] [Full Text] [Related]

  • 33. Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation.
    Bjerkeli V, Damås JK, Fevang B, Holter JC, Aukrust P, Frøland SS.
    Rheumatology (Oxford); 2007 Sep; 46(9):1422-7. PubMed ID: 17616549
    [Abstract] [Full Text] [Related]

  • 34. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30.
    Gerli R, Lunardi C, Bocci EB, Bobbio-Pallavicini F, Schillaci G, Caporali R, Bistoni O, Pirro M, Pitzalis C, Montecucco C.
    J Rheumatol; 2008 Jan; 35(1):14-9. PubMed ID: 18061981
    [Abstract] [Full Text] [Related]

  • 35. Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy.
    Lemarechal H, Allanore Y, Chenevier-Gobeaux C, Kahan A, Ekindjian OG, Borderie D.
    Clin Chim Acta; 2006 Oct; 372(1-2):147-53. PubMed ID: 16716286
    [Abstract] [Full Text] [Related]

  • 36. Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.
    Kuuliala A, Nissinen R, Kautiainen H, Repo H, Leirisalo-Repo M.
    Ann Rheum Dis; 2006 Jan; 65(1):26-9. PubMed ID: 15941839
    [Abstract] [Full Text] [Related]

  • 37. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC, Chung SJ, Park YB, Lee SK.
    Scand J Rheumatol; 2008 Jan; 37(3):173-8. PubMed ID: 18465450
    [Abstract] [Full Text] [Related]

  • 38. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
    Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D.
    Arthritis Rheum; 2003 Jul; 48(7):1849-52. PubMed ID: 12847678
    [Abstract] [Full Text] [Related]

  • 39. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN, Masding A, Somerville M, Gaffney K, Scott DG.
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [Abstract] [Full Text] [Related]

  • 40. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, Dougados M, Baldassare A, Ferraccioli G, Chubick A, Udell J, Cravets MW, Agarwal S, Cooper S, Magrini F.
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.